Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 3, 1997, Pages 365-370

  Villar, Hugo E ^a,b   Danel, Franck ^a   Livermore, David M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOXITIN; IMIPENEM; MECILLINAM; OUTER MEMBRANE PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM MUTANT; CROSS RESISTANCE; NONHUMAN; PROTEUS MIRABILIS;

AMDINOCILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CEFOXITIN; CELL MEMBRANE PERMEABILITY; IMIPENEM; MUTATION; PROTEUS MIRABILIS;

EID: 0030759065     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.3.365     Document Type: Article

References (24)

1. Horadam, V. W., Smilack, J. D., Montgomery, C. L. & Werringloer, J. (1980). In vitro activity of N-formimidoyl thienamycin, MK0787, a crystalline derivative of thienamycin. Antimicrobial Agents and Chemotherapy 18, 557-61.
2. Verbist, L. & Verhaegen, J. (1981). In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrobial Agents and Chemotherapy 19, 402-6.
3. Yourassowsky, E., Van der Linden, M. P. & Crokaert, F. (1990). Antibacterial effect of meropenem and imipenem on Proteus mirabilis. Journal of Antimicrobial Chemotherapy 26, 185-92.
4. Marier, R. L. (1985). Role of imipenem/cilastatin in the treatment of soft tissue infections. American Journal of Medicine 78, Suppl. 6A, 140-4.
5. Topiel, M. S., Paleologo, F. P., Goldstein, N. H., Van Ness, M., June, C., Rosenstock, J. et al. (1986). Comparative trial of imipenem and moxalactam in the treatment of serious bacterial infections. Current Therapeutic Research 40, 7-16.
6. Dirksen, M. S. C., Wintermans, R. G. F., Boerema, J. B. J. & Grimbere, J. S. F. (1986). Imipenem as monotherapy in the treatment of intensive care patients with severe infections. Journal of Antimicrobial Chemotherapy 18, Suppl. E, 145-51.
7. Norrby, S. R., Gialdroni-Grassi, G., Baquero, F., Kahan, F., Kosmidis, J., Gudmundsson, S. et al. (1986). Discussion I. Journal of Antimicrobial Chemotherapy 18, Suppl. E. 75-8.
8. Wexler, H. M. & Finegold, S. M. (1985). Impact of imipenem/cilastatin therapy on normal fecal flora. American Journal of Medicine 78, Suppl. 6A , 41-6.
9. Mehtar, S., Tsakris, A. & Pitt, T.L. (1991). Imipenem resistance in Proteus mirabilis. Journal of Antimicrobial Chemotherapy 28, 612-5.
10. Villar, H. E., Fernandez Lausi, A., Jugo, M. B. & Farinati, A. (1995). Seleccion in vitro de mutantes resistentes al imipenem en bacterias de la familia Enterobacteriaceae. In VII Congreso Argentino de Microbiologia, Abstract L7, p. 57. Asociacion Argentina de Microbiologia, Buenos Aires..
11. Neuwirth, C., Siebor, E., Duez, J. M., Pechinot, A. & Kazmierczak, A. (1995). Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. Journal of Antimicrobial Chemotherapy 36, 335-42.
12. Matthew, M., Harris, A. M., Marshall, M. J. & Ross, G. W. (1975). The use of analytical isoelectric focusing for detection and identification of β-lactamases. Journal of General Microbiology 88, 169-78.
13. Nordmann, P., Mariotte, S., Naas, T., Labia, R. and Nicolas, M.-H. (1993). Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 939-46.
14. Livermore, D. M. (1992). Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 36, 2046-8.
15. Zimmermann, W. & Rosselet, A. (1977). Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 12, 368-72.
16. Bush, K., Jacoby, G. A. & Medeiros, A. A. (1995). A functional classification scheme for β-lactamases and its correlation with molecular structures. Antimicrobial Agents and Chemotherapy 39, 1211-33.
17. Nikaido, H. (1989). Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrobial Agents and Chemotherapy 33, 1831-6.
18. Nikaido, H. (1994). Prevention of drug access to bacterial targets: permeability and active efflux. Science 264, 382-8.
19. Cohen, S. P., Yan, W. & Levy, S. B. (1993). A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria. Journal of Infectious Diseases 168, 484-8.
20. Nikaido, H. & Vaara, M. (1985). Molecular basis of bacterial outer membrane permeability. Microbiological Reviews 49, 1-32.
21. Sawai, T., Hiruma, R., Kawuna, N., Kaneko, M., Taniyasu, F. & Inami, A. (1982). Outer membrane permeation of β-lactam antibiotics in Escherichia coli, Proteus mirabilis and Enterobacter cloacae. Antimicrobial Agents and Chemotherapy 22, 585-92.
22. Spratt, B. G. (1978). Escherichia coli resistant to β-lactam antibiotics through a decrease in the affinity of a target for lethality. Nature 274, 713-5.
23. Noguchi, H., Matsuhashi, M. & Mitsuhashi, S. (1979). Comparative studies of penicillin-binding proteins in Pseudomonas aeruginosa and Escherichia coli. European Journal of Biochemistry 100, 41-9.
24. Moellering, R. C., Eliopoulos, G. M. & Sentochnik, D. E. (1989) The carbapenems: new broad spectrum β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 24, Suppl. A, 1-7.